{"product_id":"tilray-pestle-analysis","title":"Tilray Brands PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Smarter Strategic Decisions with a Complete PESTEL View\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnpack how political shifts, regulatory scrutiny, and evolving consumer trends shape Tilray Brands' trajectory in our concise PESTLE overview; ideal for investors and strategists seeking quick, actionable context. Purchase the full PESTLE analysis to access detailed risk assessments, market drivers, and strategic recommendations ready for immediate use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Federal Rescheduling Impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe reclassification of cannabis to Schedule III under the Controlled Substances Act is a transformative political shift for Tilray’s U.S. ambitions, potentially unlocking access to federal banking and research while reducing compliance costs. Removing 280E would meaningfully cut tax burdens—analysts estimate corporate tax savings could boost U.S. EBITDA margins by 5–8 percentage points on Tilray’s FY2024 U.S. revenue base (~$200–250M). Tilray can redirect savings into craft beer and hemp infrastructure, accelerating planned capital expenditures and M\u0026amp;A to capture market share as regulatory barriers erode.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Market Liberalization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpgermany progressive cannabis legalization underpins tilray late-2025 international growth with germany pillar reform and broader medical access enabling to run its german cultivation site near full capacity supporting roughly in eu revenues\u003e\n\u003c\/pgermany\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian Excise Tax Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical lobbying in Canada to reform excise taxes is vital for Tilray’s margins; industry data show excise can exceed production costs by over 20-30%, squeezing licensed producers’ profitability. In 2024 Tilray reported Canadian gross margins compressed versus international segments, citing tax pressures that reduce domestic EBITDA contribution. Tilray continues active engagement with Health Canada and Finance to push for a tax framework aligned with a maturing market and 2025 revenue targets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Export Protocols\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe political framework for international medical cannabis trade shapes Tilray Brands’ access to Australia and Latin America; in FY2024 Tilray reported 28% of net revenue from international markets, making trade rules material to growth.\u003c\/p\u003e\n\u003cp\u003eModifications to bilateral agreements or import quotas can compress distribution margins—Tilray’s gross margin was 25.4% in FY2024—and require pricing and logistics adjustments.\u003c\/p\u003e\n\u003cp\u003eTilray monitors geopolitical shifts and updates compliance to align with INCB and UN narcotics control changes, maintaining cross-border licenses in 15 countries as of 2025.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28% of revenue from international markets (FY2024)\u003c\/li\u003e\n\u003cli\u003eGross margin 25.4% (FY2024)\u003c\/li\u003e\n\u003cli\u003eLicenses in 15 countries (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S. Farm Bill and Hemp Policy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003e2024–25 U.S. Farm Bill amendments raised hemp-derived cannabinoid potency thresholds and clarified interstate commerce rules, expanding marketable CBD\/THC-O concentrations and lowering compliance costs for manufacturers; this could increase addressable market for Tilray’s wellness and infused non-alcoholic drinks, where U.S. CBD beverage sales reached about $360 million in 2024.\u003c\/p\u003e\n\u003cp\u003ePolitical friction between federal regulators and state cannabis regimes forces Tilray’s executive team to prioritize dual-track compliance and supply-chain segmentation to protect projected beverage segment margins and avoid $10–25 million in potential recall or relabeling costs per major product line.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024–25 Farm Bill raised hemp potency limits, easing product formulation\u003c\/li\u003e\n\u003cli\u003eU.S. CBD beverages market ≈ $360M in 2024; growth tied to regulatory clarity\u003c\/li\u003e\n\u003cli\u003eTilray focuses on compliance and supply-chain segmentation to mitigate $10–25M product risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTilray: U.S. rescheduling + Germany lift EBITDA ~5–8pt; €220M EU market, $360M CBD\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFederal rescheduling to Schedule III and removal of 280E could lift U.S. EBITDA margins by ~5–8 pts on Tilray’s ~$200–250M FY2024 U.S. revenue; Germany legalization supports ~€220M EU cannabis revenues (2024–25); 28% of net revenue was international (FY2024) with gross margin 25.4% (FY2024); licenses in 15 countries (2025); U.S. CBD beverage market ≈ $360M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 U.S. revenue\u003c\/td\u003e\n\u003ctd\u003e$200–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential EBITDA uplift\u003c\/td\u003e\n\u003ctd\u003e+5–8 pts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU cannabis revenues (2024–25)\u003c\/td\u003e\n\u003ctd\u003e€220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational share (FY2024)\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e25.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses (2025)\u003c\/td\u003e\n\u003ctd\u003e15 countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. CBD beverages (2024)\u003c\/td\u003e\n\u003ctd\u003e$360M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect Tilray Brands across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current market and regulatory data to identify threats and opportunities for executives, investors, and strategists.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, visually segmented PESTLE summary of Tilray Brands that eases meeting prep, highlights external risks and opportunities for strategic alignment, and can be dropped into presentations or shared across teams for quick decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest Rate Environment and Capital Cost\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs of late 2025, higher global interest rates—US Fed funds around 5.25–5.50%—have raised Tilray's weighted average cost of capital, historically constraining large, debt-funded acquisitions.\u003c\/p\u003e\n\u003cp\u003eStabilizing rates through 2024–2025 reduced refinancing risk, allowing more predictable interest expense and supporting Tilray's aggressive M\u0026amp;A in craft beer and cannabis.\u003c\/p\u003e\n\u003cp\u003eMaintaining net debt\/EBITDA near targeted levels (Telray reported pro forma leverage ~2.5x in FY2024) remains critical to preserve acquisition firepower and credit access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsumer Spending Power and Inflation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInflation-driven swings in disposable income have pressured consumer spending, with US CPI rising 3.4% in 2024 and real wages lagging, reducing demand for Tilray’s premium craft beer while recreational cannabis—showing 6–8% annual growth in key markets in 2024—remains more resilient; Tilray’s multi-tier pricing across cannabis and beer, plus 2024 revenue diversification (cannabis ~62%, adult beverages ~25%), helps buffer downturns and protect overall margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTilray's operations across Canada, Europe and the United States expose it to meaningful FX risk; in FY2024, currency moves contributed to a reported CAD 120 million of non-cash translation adjustments. Fluctuations in the U.S. dollar versus the euro and Canadian dollar have the potential to swing quarterly EBITDA by double-digit percentages for international revenue streams. Management reported using forward contracts and options, with hedges covering over 60% of forecasted FX exposure as of Q3 2025 to stabilize margins. These hedging programs aim to limit volatility-driven swings in reported earnings and cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of the Craft Beer Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe U.S. craft beer consolidation let Tilray acquire underperforming labels at low multiples; in 2024 Tilray’s beverage division grew revenue to about US$460M, aided by several acquisitions priced below book value.\u003c\/p\u003e\n\u003cp\u003eCentralized distribution cut COGS and SG\u0026amp;A, driving estimated mid-single-digit margin expansion and unlocking cost synergies that turned beverage alcohol into a steady cash generator.\u003c\/p\u003e\n\u003cp\u003eThat cash flow funded cannabis R\u0026amp;D and capacity expansion, supporting Tilray’s higher-growth cannabis initiatives without dilutive capital raises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 beverage revenue ≈ US$460M\u003c\/li\u003e\n\u003cli\u003eAcquisitions at depressed valuations, boosting margins by mid-single-digits\u003c\/li\u003e\n\u003cli\u003eCentralized distribution → significant COGS\/SG\u0026amp;A savings\u003c\/li\u003e\n\u003cli\u003eSteady beverage cash flow funds cannabis growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain and Commodity Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpeconomic shifts in aluminum glass and agricultural input prices have trimmed tilray brands gross margins rose while global fertilizer averaged above levels pressuring cogs packaging expenses.\u003e\n\u003cpsupply chain disruptions and a european energy price surge electricity up to in some months notably increased operating costs at tilray medical cannabis facilities reducing regional margins.\u003e\n\u003cptilray mitigates volatility through long-term supplier contracts and vertical integration by the company reported over of key inputs secured via multi-year agreements increasing in-house cultivation to lower input spend.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAluminum +18% (2024) and fertilizer +12% vs 2020 elevated packaging and cultivation COGS\u003c\/li\u003e\n\u003cli\u003eEuropean energy spikes (up to 3x) pressured medical cannabis facility margins\u003c\/li\u003e\n\u003cli\u003eOver 60% of key inputs under multi-year contracts by 2025; growing vertical integration\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptilray\u003e\u003c\/psupply\u003e\u003c\/peconomic\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStable rates and strong beverage cashflow preserve 2.5x leverage and M\u0026amp;A capacity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher rates (Fed 5.25–5.50% in late 2025) raised WACC but stabilizing 2024–25 rates cut refinancing risk; pro forma leverage ~2.5x FY2024 preserved M\u0026amp;A capacity. Revenue mix (cannabis ~62%, beverages ~25% in 2024) and beverage cash flow (≈US$460M 2024) buffer demand swings amid 2024 CPI +3.4% and input cost pressures (aluminum +18%, fertilizer +12% vs 2020). Hedging covered \u0026gt;60% FX exposure by Q3 2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed funds (late 2025)\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeverage (pro forma FY2024)\u003c\/td\u003e\n\u003ctd\u003e~2.5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeverage revenue 2024\u003c\/td\u003e\n\u003ctd\u003e≈US$460M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCannabis revenue share 2024\u003c\/td\u003e\n\u003ctd\u003e~62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI 2024\u003c\/td\u003e\n\u003ctd\u003e+3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAluminum 2024\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertilizer vs 2020\u003c\/td\u003e\n\u003ctd\u003e+12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedges (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60% coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eTilray Brands PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Tilray Brands PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategy or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751395668345,"sku":"tilray-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/tilray-pestle-analysis.png?v=1772230901","url":"https:\/\/matrixbcg.com\/products\/tilray-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}